Horizon Pharma PLC (HZNP) Downgraded to Neutral at Mizuho

Henrietta Strickland
June 19, 2017

The Firm operates through online video advertising services segment. Quantbot Lp invested in 0.07% or 39,888 shares. Tcw Group Inc who had been investing in Horizon Pharma Plc for a number of months, seems to be less bullish one the $1.66 billion market cap company. On Tuesday, November 10 the stock rating was maintained by Mizuho with "Buy". Finally, Mizuho reiterated a "buy" rating and issued a $25.00 target price on shares of Horizon Pharma PLC in a research note on Wednesday, February 22nd. The stock of Horizon Pharma PLC (NASDAQ:HZNP) has "Underweight" rating given on Thursday, December 3 by Morgan Stanley. Miller Tabak initiated TJX Companies Inc (NYSE:TJX) rating on Friday, June 24. S&P Research maintained the shares of TJX in report on Wednesday, August 19 with "Buy" rating. The firm has "Outperform" rating given on Wednesday, November 16 by Wedbush. As per Tuesday, September 13, the company rating was maintained by Mizuho. Guardian Investment Management, a California-based fund reported 117,662 shares.

Wynnefield Capital Inc holds 0.51% of its portfolio in Nevada Gold & Casinos for 772,188 shares. Graybill Bartz & Assoc Ltd. now owns 165,260 shares of the biopharmaceutical company's stock worth $2,443,000 after buying an additional 2,620 shares during the period. Cornerstone Advsrs Inc reported 847 shares. Goldman Sachs Grp Inc has invested 0% in Insulet Corporation (NASDAQ:PODD). Envestnet Asset Management, a Illinois-based fund reported 120,714 shares.

It closed at $2.29 lastly. It has outperformed by 8.30% the S&P500.

Investors sentiment decreased to 1.02 in 2016 Q4.

Beta is also an important valuation ratio for analyzing the stock of the company, HZNP has Beta of 1.41 while its industry and Sector's beta remains at 0.88 and 0.86 respectively.

Horizon Pharma Ord (NASDAQ:HZNP) has grabbed attention from the analysts, when it saw a value decrease of -5.12% or -0.55 points in the last trading session to close at $10.2.

Horizon Pharma plc (HZNP) reported sales (ttm) of 997.3 Million, whereas, 6 number of analysts estimated the mean sale of 236.47 million. The biopharmaceutical company reported $0.21 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.25 by $0.04.

Press coverage about Horizon Pharma PLC (NASDAQ:HZNP) has trended somewhat positive recently, according to AlphaOne Sentiment Analysis. State Street Corp reported 4.34M shares or 0.01% of all its holdings. Edge Wealth Management Limited Co holds 10,000 shares or 0.06% of its portfolio. Voya Invest Mgmt Llc owns 24,426 shares or 0% of their U.S. portfolio. Swiss Bancorporation holds 235,356 shares or 0.01% of its portfolio. Vanguard Group Incorporated reported 0.01% stake. Redwood Invests Limited Liability Corp invested in 0.67% or 459,386 shares. Redwood Invs Ltd Liability Co accumulated 459,386 shares. Parkwood Ltd Liability has invested 0.25% in Horizon Pharma PLC (NASDAQ:HZNP). Comml Bank Of America De invested in 565,673 shares or 0% of the stock. Paloma Prtnrs invested in 0% or 28,571 shares. More interesting news about Horizon Pharma PLC (NASDAQ:HZNP) were released by: Zacks.com and their article: "Horizon Pharma (HZNP) Up 11.3% Since Earnings Report: Can It Continue?" published on June 12, 2017 as well as Streetinsider.com's news article titled: "Horizon Pharma (HZNP) to Sell European Marketing Rights to PROCYSBI and EMEA ..." with publication date: May 23, 2017. Wolverine Asset Mngmt Ltd Limited Liability Company reported 70,000 shares stake. The correct version of this piece of content can be accessed at https://sportsperspectives.com/2017/06/17/lsv-asset-management-continues-to-hold-stake-in-horizon-pharma-plc-hznp-updated-updated.html.

Since March 3, 2017, it had 0 insider purchases, and 3 selling transactions for $2.06 million activity. $94,800 worth of Horizon Pharma PLC (NASDAQ:HZNP) shares were bought by GREY MICHAEL G. Past 5 years growth of the company observed at 26.19%, and for the next five years the analysts that follow the company are expecting its growth at 12.9%. About 1.11 million shares traded. It has underperformed by 44.83% the S&P500.The move comes after 5 months positive chart setup for the $1.70B company.

Stevens Capital Management LP bought a new position in Horizon Pharma PLC during the first quarter valued at about $173,000. This company shares are 25.32% off its target price of $17.42 and the current market capitalization stands at $970.08M. The Firm is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. Morgan Stanley upgraded it to "Equal-Weight" rating and $24 target in Monday, July 11 report.

- Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Horizon Pharma PLC and related companies.

Other reports by Click Lancashire

Discuss This Article

FOLLOW OUR NEWSPAPER